Federal Register / Vol. 70, No. 22 / Thursday, February 3, 2005 / Notices 5689

(21 CFR 10.205), representatives of the 

electronic media may be permitted, 

subject to certain limitations, to 

videotape, film, or otherwise record 

FDA’s public administrative 

proceedings, including presentations by 

participants. The hearing will be 

transcribed as stipulated in § 15.30(b). 

The transcript will be available on the 

Internet at http://www.fda.gov/ohrms/

dockets, and orders for copies of the 

transcript can be placed at the meeting 

or through the Division of Dockets 

Management (see ADDRESSES).

Any handicapped persons requiring 

special accommodations to attend the 

hearing should direct those needs to the 

contact person (see FOR FURTHER

INFORMATION CONTACT).

To the extent that the conditions for 

the hearing, as described in this notice, 

conflict with any provisions set out in 

part 15, this notice acts as a waiver of 

these provisions as specified in 

§ 15.30(h).

IV. Comments

Interested persons may submit to the 

Division of Dockets Management (see 

ADDRESSES) written or electronic notices 

of participation and comments for 

consideration at the hearing (see DATES). 

Submit a single copy of written or 

electronic notices of participation and 

comments, or two paper copies of any 

mailed notices of participation and 

comments, except that individuals may 

submit one copy. Comments are to be 

identified with the docket number 

found in brackets in the heading of this 

document. Received comments may be 

seen in the Division of Dockets 

Management between 9 a.m. and 4 p.m., 

Monday through Friday.

Dated: January 28, 2005.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 05–2094 Filed 1–31–05; 3:37 pm]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on Infant 

Mortality; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), notice is hereby given 

of the following meeting: 

Name: Advisory Committee on Infant 

Mortality (ACIM). 

Dates and Times: March 1, 2005, 9 

a.m.–5 p.m. March 2, 2005, 8:30 a.m.–

3 p.m. 

Place: Sheraton National Hotel, 900 

South Orme Street, Arlington, Virginia 

22204, (703) 521–1900. 

Status: The meeting is open to the 

public with attendance limited to space 

availability. 

Purpose: The Committee provides 

advice and recommendations to the 

Secretary of Health and Human Services 

on the following: Department programs 

that are directed at reducing infant 

mortality and improving the health 

status of pregnant women and infants; 

factors affecting the continuum of care 

with respect to maternal and child 

health care, including outcomes 

following childbirth; strategies to 

coordinate the variety of Federal, State, 

local and private programs and efforts 

that are designed to deal with the health 

and social problems impacting on infant 

mortality; and the implementation of 

the Healthy Start program and Healthy 

People 2010 infant mortality objectives. 

Agenda: Topics that will be discussed 

include the following: Improving 

Perinatal Data; Neonatal Intensive Care 

and Ethical Issues; and Provider 

Reimbursement Issues. Substantial time 

will be spent in small group and full 

Committee discussions aimed at 

formulating the ACIM issues agenda. 

Proposed agenda items are subject to 

change as priorities indicate. 

Time will be provided for public 

comments limited to five minutes each; 

comments are to be submitted no later 

than February 15, 2005.

FOR FURTHER INFORMATION CONTACT:

Anyone requiring information regarding 

the Committee should contact Peter C. 

van Dyck, M.D., M.P.H., Executive 

Secretary, ACIM, Health Resources and 

Services Administration (HRSA), Room 

18–05, Parklawn Building, 5600 Fishers 

Lane, Rockville, MD 20857, Telephone: 

(301) 443–2170. 

Individuals who are submitting public 

comments or who have questions 

regarding the meeting should contact 

Ann M. Koontz, C.N.M., Dr. P.H., HRSA, 

Maternal and Child Health Bureau, 

telephone: (301) 443–6327, e-mail: 

akoontz@hrsa.gov.

Dated: January 31, 2005. 

Steven A. Pelovitz, 

Associate Administrator for Administration 

and Financial Management.

[FR Doc. 05–2102 Filed 2–2–05; 8:45 am] 

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908), 

on September 30, 1997 (62 FR 51118), 

and on April 13, 2004 (69 FR 19644). 

A notice listing all currently certified 

laboratories is published in the Federal 

Register during the first week of each 

month. If any laboratory’s certification 

is suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end, 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http://workplace.samhsa.gov

and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh or Dr. Walter Vogl, 

Division of Workplace Programs, 

SAMHSA/CSAP, Room 2–1035, 1 Choke 

Cherry Road, Rockville, Maryland 

20857; (240) 276–2600 (voice), (240) 

276–2610 (fax).

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Mandatory 

Guidelines, ‘‘Certification of 

Laboratories Engaged in Urine Drug 

Testing for Federal Agencies,’’ sets strict 

standards that laboratories must meet in 

order to conduct drug and specimen 

validity tests on urine specimens for 

Federal agencies. To become certified, 

an applicant laboratory must undergo 

three rounds of performance testing plus 

an on-site inspection. To maintain that